Search
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalIn October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions. … Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigationalIt was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name … [A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management
Nabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalNabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA … It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics.
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnIt was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.
Nonacog beta pegol
go.drugbank.com/drugs/DB13933ApprovedInvestigational[A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017.
Products: REFİXİA 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, REFİXİA 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖRGadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigational[A263076] Initially approved by the FDA in 1992, gadoteridol received additional approval in 2020 for use in pediatric patients less than 2 years old.[L49876]
Mechlorethamine
go.drugbank.com/drugs/DB00888ApprovedInvestigationalThe FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]
Olezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.
Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL)